Damage to myelin – the insulating fatty sheath that allows long-range neuronal communication – is at the root of multiple sclerosis (MS). But it is also behind other forms of brain injury – notably, developing oligodendrocytes are very sensitive to conditions of low oxygen, and problems at birth can lead to permanent damage that shows itself as cerebral palsy or cognitive deficits. Read More
Sorrento Therapeutics Inc., of San Diego, received a Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases in support of its antibody therapeutics and vaccines for Staphylococcus aureus, including methicillin-resistant strains. The Phase I grant is worth $600,000 over two years, with possible Phase II funding of $1 million per year for three years. Read More
Sylentis SA, of Madrid, Spain, a subsidiary of Grupo Zeltia, presented two posters at the World Glaucoma Congress in Paris. One poster showed that topical candidate SYL040012, administered to healthy volunteers with normal intraocular pressure (IOP), demonstrated excellent local tolerance and showed a decline in IOP in most of the subjects. Read More
Tetragenetics Inc., of Cambridge, Mass., appointed Marco Cacciuttolo president and CEO. It also named Ben Machielse and Robert Gailus to its board. Read More
Archimedes Pharma Ltd.'s Lazanda isn't the first fentanyl product to get the FDA's nod for breakthrough cancer pain, but its pain-free risk evaluation and mitigation strategy (REMS) and intranasal delivery could give it an edge in the U.S. market once it launches in the fall. Read More
